Clinical Trials

Enrolling Trials

61-70  of  92  for  "cancer"
10323, Cancer Moonshot Biobank Research Protocol
Onitilo, Adedayo A
Miscellaneous Neoplasm
Adult
To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Brandt, Jon
Late Effects
Child
Neuropsychological and behavioral assessments are a crucial component of monitoring for late effects in patients being treated, normally quite aggressively, for cancer. This is especially true for patients that are exposed to potentially neurotoxic therapies. However, lack of compliance with assessment schedules, variations in assessment schedules and neuropsychological measures utilized across studies, as well as overly complex and long neuropsychological assessments have proved to be problematic to the assessment process within the Children's Oncology Group (COG). In order to remediate these problems, a streamlined and standardized neuropsychological and behavioral assessment battery has been developed. The COG Standard Neuropsychological and Behavioral Battery is a focused assessment of critical functional domains that have been empirically shown to be most affected by childhood cancer, its treatment, or other disease related factors. This battery was designed to provide a brief measure of neuropsychological and behavioral function in order to strike a balance between research goals, the clinical needs of the patient, and time constraints on the institutional neuropsychologist/psychologist. The battery of tests will take only about 1 hour to administer and all patients will be tested at 3 standardized timepoints. Parent-completed questionnaires will also be utilized to gather information about the patient's function, specifically in terms of attention, memory, executive abilities, and behavioral/social/emotional adaptation.
Welter, Stacy L
(715) 221-6492
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Husak, Michael
Lung - Lung
Adult
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Hurley, Alexa A
(715) 393-1019
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
S1802, Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. standard systemic therapy alone.
Bulgrin, Angela M
(715) 221-7261
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
S1918-A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
Fagbemi, Seth O
Other Blood Cancers - Non-Hodgkin's
Adult
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Lee, David
Lung - Lung
Adult
This trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Yeboah, Isaac
Stomach, Intestine, Gut - Pancreas
Adult
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Bulgrin, Angela M
(715) 221-7261
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
S1931, Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Fagbemi, Seth O
Kidney Tumors
Adult
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Tesmer, Brooke
(715) 221-7330
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
S1827, MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Ly, Bevan
Lung - Lung
Adult
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI  54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
NRG-GU011-A Phase II Double-Blinded, Placebo- Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Lee, David
Bladder, Prostate, Kidney - Prostate
Adult
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476